Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer Reports Solid Q4 Earnings But Offers Weaker Outlook Stock undervalued as recent weak performance doesn’t reflect long-term outlook.

Pfizer Inc. raised the lower end of its earnings forecast for the year and reiterated its sales expectations despite unfavorable currency trends. The drugmaker continues to project its new Covid ...

Pfizer (PFE) is set to release its Q4 2023 results amid rising bearish bets on its earnings outlook due to headwinds against its COVID-19 franchise. Read more here.

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year ...

Pfizer reported third-quarter revenue and adjusted profit that blew past expectations. The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales ...

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

Pfizer said Tuesday it now expects 2024 adjusted earnings between $2.45 a share to $2.65 a share, 30 cents higher at the midpoint than its prior projection. The shares rose as much as 1.4% at the ...

We think PFE stock may see higher levels post Q3 announcement on a revenue and earnings beat. If the company were to raise its full-year outlook, it will likely bode well with the investors.

Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?